biostudies-literatureWang ZNational Natural Science Foundation of China738https://www.ebi.ac.uk/biostudies/studies/S-EPMC7483467biostudies-literatureUnknown11(9)Histone deacetylase 7 (HDAC7), a member of class IIa HDACs, has been described to be an important regulator for B cell development and has a potential role in B cell acute lymphoblastic leukemia (B-ALL). CC1007, a BML-210 analog, is designed to indirectly inhibit class IIa HDACs by binding to myocyte enhancer factor-2 (MEF2) and blocking the recruitment of class IIa HDACs to MEF2-targeted genes to enhance the expression of these targets. In this study, we investigated the anticancer effects of CC1007 in breakpoint cluster region-Abelson 1 fusion gene-negative (BCR-ABL1^-) pre-B-ALL cell lines and primary patient-derived BCR-ABL1^- pre-B-ALL cells. CC1007 had obvious antileukemic activity toward pre-B-ALL cells in vitro and in vivo; it also significantly prolonged medianCell death & diseaseA small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1^- pre-B-ALL.PMC7483467815001718160018381470323Zhang GChen LLiu SLi RDeng MCheng ZPeng HZhang YHu GChen YLuo YWang ZZhu SXu YfalseA small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1^- pre-B-ALL.Histone deacetylase 7 (HDAC7), a member of class IIa HDACs, has been described to be an important regulator for B cell development and has a potential role in B cell acute lymphoblastic leukemia (B-ALL). CC1007, a BML-210 analog, is designed to indirectly inhibit class IIa HDACs by binding to myocyte enhancer factor-2 (MEF2) and blocking the recruitment of class IIa HDACs to MEF2-targeted genes to enhance the expression of these targets. In this study, we investigated the anticancer effects of CC1007 in breakpoint cluster region-Abelson 1 fusion gene-negative (BCR-ABL1^-) pre-B-ALL cell lines and primary patient-derived BCR-ABL1^- pre-B-ALL cells. CC1007 had obvious antileukemic activity toward pre-B-ALL cells in vitro and in vivo; it also significantly prolonged median2020-01-01T00:00:00Z2020 Sep2025-04-18T18:31:22.506Z2020-09-25T07:03:21ZS-EPMC74834673291318810.1038/s41419-020-02949-1